Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.

MLA

Middha, Sumit, et al. “Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.” JCO Precision Oncology, vol. 3, 2019. EBSCOhost, https://doi.org/10.1200/PO.18.00321.

APA

Middha, S., Yaeger, R., Shia, J., Stadler, Z. K., King, S., Guercio, S., Paroder, V., Bates, D. D. B., Rana, S., Diaz, L. A., Jr, Saltz, L., Segal, N., Ladanyi, M., Zehir, A., & Hechtman, J. F. (2019). Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precision Oncology, 3. https://doi.org/10.1200/PO.18.00321

Chicago

Middha, Sumit, Rona Yaeger, Jinru Shia, Zsofia K Stadler, Sarah King, Shanna Guercio, Victoriya Paroder, et al. 2019. “Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.” JCO Precision Oncology 3. doi:10.1200/PO.18.00321.